24-018_SS_AG Bioinformatician - Hematopoietic Stem Cell Biology and Leukemogenesis
Bioinformatician - Hematopoietic Stem Cell Biology and Leukemogenesis
Ref.: 24-018_SS_AG
About the research group
The Hematopoietic Stem Cell Biology & Leukemogenesis research group offers good conditions and an excellent research environment and facilities.
Pediatric MDS/AML (pMDS/pAML) are considered a rare disease characterized by a variety of genetic and chromosomal abnormalities. The genetic characteristics of pMDS/pAML are slightly different from those of adult counterpart. Very few targeted therapies are available, leaving HSC transplantation the only curative option with significant toxicities; hence there is a clear unmet medical need. The research in our laboratory follows two lines of investigation: one aims to understand the molecular mechanism of these syndromes by studying haematopoiesis on single cell level and by using in vitro and in vivo models; and the other focusing in improving the treatment of pMDS/pAML, based on a new genomic methodology that will not only determine the response to treatment, but also to identify new drug combinations that can target the resistant cells and adapt the treatment to each child with AML, thus improving the overall survival. We employ a variety of methodologies to support our research, including mouse and iPSC disease modeling, CRISPR/Cas9-based genome engineering, and single cell proteogenomics, among others. Leveraging these technologies and building upon our research program, we intended to improve the bench-to-bed translation of findings for better management and increase the cure rate of these children by favouring personalized therapies.
About the role
-
Analysis of bioinformatic dataset
-
Discussion of the results
-
Participate in group meetings and scientific discussions.
-
Engage in career development activities, outreach and soft skill training.
Job requirements
Professional experience
Education and training
Technical & soft skills
-
Knowledge of statistical programs (SPSS, STATA, R)
-
Knowledge of the programming and scripting languages such as Python
-
Knowledge of the Unix ecosystem and ability to work on a HPC (High Performance Computer)
-
Knowledge of pipelines of bulk sequence analysis, such as RNA-seq and ATAC-seq
-
Experience in the analysis of sigle-cell data and knowledge of libraries such as Seurat of Scanpy
-
Skills in written and oral communication
-
Initiative, good capacity for planning and organising the work schedule and a good predisposition to work in a multidisciplinary way with the rest of the professionals in the team
-
Analytical and critical thinking
-
Good communication skills and motivation to achieve project objectives
Languages
We will value, but not required
- Teamwork
- Motivation, initiative and learning ability
What do we offer
-
-
Estimated start date: 01/03/2024
-
Contract duration: 36 months
-
Estimated annual gross salary: 27.000 €
-
You will be part of a multicultural team. We have a fun loving and friendly international work environment.
-
Flexible working schedule - We know you have a life outside of work and we will work with you to make sure it's kept that way.
-
Possibility to work some days in remote - Teleworking
-
26 working days of holiday per year
-
System of accumulated hours for employees, from 88 to 104 hours depending on the year (11 to 13 working days), to attend to personal matters.
-
-
Benefits of constant training are offered
-
We offer and promote diverse and inclusive conditions. Applicants are made free from any discrimination. Specifically IDIBELL works to improve gender equality in all areas with the aim of achieving gender balance, but maintaining the most scrupulous respect to any choice at the level of gender identity. Please express yourself freely, safely and non-binarily, if that's the case.
Deadline: Please submit your application by 17/03/2024
Data protection notice
In compliance with the obligations established in the General Regulation of Data Protection (RGPD), which is the Regulation (EU) 2016/679 of the Parliament and of the Council, of April 27, 2016, and the Organic Law 3/2018, of December 5, Protection of Personal Data and guarantee of digital rights, it is reported that the Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), CIF G58863317, with address Av. Granvia de l'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, will process your personal data, as the controller, to apply for the position, maintain communication concerning the status of the candidature, to access the delivered CV; to compare that your data is in accordance with the offers announced by IDIBELL and to verify, where appropriate, that the information provided is accurate.
You can find more information in our Privacy Policy at https://idibell.cat/en/privacy-policy-2/, request more information about the data processing carried out and exercise your rights of access, rectification, deletion, opposition, portability, limitation of processing by sending a request at email: dataprotection@idibell.cat. If you consider that you have not obtained satisfaction in exercising your rights, you may submit a claim to Catalan Data Protection Authority.
Our institute
IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). The research focuses of IDIBELL are cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the pivots on which researchers work every day in order to improve the quality of life of citizens.
Observations
The 'HR Excellence in Research' award represents IDIBELL’s commitment to the implementation of Human Resources policies, which oversee the attracting and development of talent in an open, transparent, and based on personal merit, in alignment with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment Researchers (Charter and Code).
IDIBELL is committed to the principles of the Code of Conduct for the Recruitment of Researchers of the European Commission and the implementation of open, transparent and merit-based recruitment (OTMR).
Funded by the Carlos III Health Institute (ISCIII), under the "FORTALECE Program of the Ministry of Science and Innovation," through the project with reference number FORT23/00032. With the institutional support of the CERCA Programme/Generalitat de Catalunya.